VolitionRx Issues 2025 Business Review

VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, issues a Business Review of 2025.

Review of the Year by Cameron Reynolds, Group Chief Executive Officer

As 2025 draws to a close, I would like to take this opportunity to look back on the year's key milestones and look to the opportunities ahead.

Before diving into the detail, I would like to take a moment to reflect on our founding mission. We set out over fifteen years ago to help save lives and improve outcomes for millions of patients worldwide, and I could not be prouder of the progress we are making towards that goal.

In this fourth quarter we not only received our first order for the Nu.Q® Cancer assays for clinical certification ahead of routine clinical use in lung cancer, but we also announced the inclusion of our Nu.Q® NETs assay in a real-world interventional evaluation of early detection of sepsis, in a government-backed (~$7.3 million) program in France. Our tests are about to be used in both these devastating diseases to help save lives in real world hospital settings: an extremely proud moment for our entire team.

Cancer and sepsis are leading causes of death, accounting for approximately a third of deaths worldwide1-3. With the first clinical use now imminent, we are about to be part of the solution, through simple, easy to use, low-cost tests.